A Multicentre Randomised, Double-Blind, Placebo-controlled, Study to Evaluate the efficAcy and Safety of Oral IVErmectin Tablets in the Prevention of COVID-19
Latest Information Update: 19 Apr 2023
At a glance
- Drugs Ivermectin (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms SAIVE
- Sponsors MedinCell S.A.
- 17 Apr 2023 According to a MedinCell S.A. media release, data from this study will be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
- 05 Jan 2023 Status changed from recruiting to completed.
- 05 Jan 2023 According to a MedinCell S.A. media release, Primary endpoint (COVID-19 prophylaxis) has been met.